{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:41Z","timestamp":1740107441515,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institues of health","doi-asserted-by":"crossref","award":["PO1 CA15396"],"award-info":[{"award-number":["PO1 CA15396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00280-017-3499-y","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T02:54:53Z","timestamp":1513133693000},"page":"347-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients"],"prefix":"10.1007","volume":"81","author":[{"given":"L. K.","family":"Schoch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Asiama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hurtt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"3499_CR1","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1038\/sj.bjc.6603535","volume":"96","author":"E Petroulakis","year":"2007","unstructured":"Petroulakis E, Mamane Y, Le Bacquer O et al (2007) mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 96:R11\u2013R15","journal-title":"Br J Cancer"},{"key":"3499_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","volume":"82","author":"CM Hartford","year":"2007","unstructured":"Hartford CM, Ratain MJ (2007) Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82:381\u2013388","journal-title":"Clin Pharmacol Ther"},{"key":"3499_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bjh.12780","volume":"165","author":"M Wang","year":"2014","unstructured":"Wang M, Popplewell LL, Collins RH Jr et al (2014) Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol 165:510\u2013518","journal-title":"Br J Haematol"},{"key":"3499_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.12845","volume":"166","author":"A Conconi","year":"2014","unstructured":"Conconi A, Raderer M, Franceschetti S et al (2014) Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol 166:69\u201376","journal-title":"Br J Haematol"},{"key":"3499_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Reeder CB, LaPlant BR et al (2011) A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25:341\u2013347","journal-title":"Leukemia"},{"key":"3499_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-015-3599-5","volume":"154","author":"DA Yardley","year":"2015","unstructured":"Yardley DA, Bosserman LD, O\u2019Shaughnessy JA et al (2015) Paclitaxel, bevacizumab, and everolimus\/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. Breast Cancer Res Treat 154:89\u201397","journal-title":"Breast Cancer Res Treat"},{"key":"3499_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP (2004) Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43:83\u201395","journal-title":"Clin Pharmacokinet"},{"key":"3499_CR8","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M et al (2006) Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165\u20135173","journal-title":"Clin Cancer Res"},{"key":"3499_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","volume":"38","author":"M Shipkova","year":"2016","unstructured":"Shipkova M, Hesselink DA, Holt DW et al (2016) Therapeutic Drug monitoring of everolimus: a consensus report. Ther Drug Monit 38:143\u2013169","journal-title":"Ther Drug Monit"},{"key":"3499_CR10","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3109\/10428194.2011.594191","volume":"52","author":"DE Gladstone","year":"2011","unstructured":"Gladstone DE, Bolanos-Meade J, Huff CA et al (2011) High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma 52:2076\u20132081","journal-title":"Leuk Lymphoma"},{"key":"3499_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06210.x","volume":"134","author":"K Wanner","year":"2006","unstructured":"Wanner K, Hipp S, Oelsner M et al (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475\u2013484","journal-title":"Br J Haematol"},{"key":"3499_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.leu.2404471","volume":"21","author":"T Haritunians","year":"2007","unstructured":"Haritunians T, Mori A, O\u2019Kelly J et al (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21:333\u2013339","journal-title":"Leukemia"},{"key":"3499_CR13","unstructured":"Yu B, DiBussolo J, Van Natta K, Kozak M (2014) Quantitation of immunosuppressant drugs in whole blood using the prelude-SPLC system and TSQ endura mass spectrometer for reasearch. \n                    https:\/\/assets.thermofisher.com\/TFS-Assets\/CMD\/Application-Notes\/AN-64043-Immunosupressants-Whole-Blood-AN604-EN-HR.pdf\n                    \n                  . Accessed 1 Oct 2017"},{"key":"3499_CR14","unstructured":"Novartis (2016) Affinitor (everolimus) tablets prescribing information. \n                    https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/afinitor.pdf\n                    \n                  . Accessed 1 Oct 2017"},{"key":"3499_CR15","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/annonc\/mdl393","volume":"18","author":"E Nitta","year":"2007","unstructured":"Nitta E, Izutsu K, Sato T et al (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18:364\u2013369","journal-title":"Ann Oncol"},{"key":"3499_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/ehm.11.62","volume":"4","author":"D Tesfa","year":"2011","unstructured":"Tesfa D, Palmblad J (2011) Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 4:619\u2013625","journal-title":"Expert Rev Hematol"},{"key":"3499_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/annonc\/mdv624","volume":"27","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Shin DY, Kim JS et al (2016) A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol 27:712\u2013718","journal-title":"Ann Oncol"},{"key":"3499_CR18","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1038\/leu.2015.164","volume":"29","author":"IM Ghobrial","year":"2015","unstructured":"Ghobrial IM, Redd R, Armand P et al (2015) Phase I\/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed\/refractory Waldenstrom macroglobulinemia. Leukemia 29:2338\u20132346","journal-title":"Leukemia"},{"key":"3499_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00280-014-2474-0","volume":"74","author":"AJ McRee","year":"2014","unstructured":"McRee AJ, Davies JM, Sanoff HG et al (2014) A phase I trial of everolimus in combination with 5-FU\/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemother Pharmacol 74:117\u2013123","journal-title":"Cancer Chemother Pharmacol"},{"key":"3499_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clgc.2014.12.011","volume":"13","author":"R Kanesvaran","year":"2015","unstructured":"Kanesvaran R, Watt K, Turnbull JD et al (2015) A Single-Arm Phase 1b Study of everolimus and sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 13:319\u2013327","journal-title":"Clin Genitourin Cancer"},{"key":"3499_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","volume":"126","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Reeder C, Han JJ et al (2015) The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood 126:328\u2013335","journal-title":"Blood"},{"key":"3499_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.eururo.2015.08.035","volume":"69","author":"T Powles","year":"2016","unstructured":"Powles T, Wheater M, Din O et al (2016) A Randomised Phase 2 Study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur Urol 69:450\u2013456","journal-title":"Eur Urol"},{"key":"3499_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdu009","volume":"25","author":"HS Rugo","year":"2014","unstructured":"Rugo HS, Pritchard KI, Gnant M et al (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25:808\u2013815","journal-title":"Ann Oncol"},{"key":"3499_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mdv612","volume":"27","author":"RJ Motzer","year":"2016","unstructured":"Motzer RJ, Alyasova A, Ye D et al (2016) Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 27:441\u2013448","journal-title":"Ann Oncol"},{"key":"3499_CR25","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968\u2013977","journal-title":"Lancet"},{"key":"3499_CR26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(15)00051-0","volume":"16","author":"SA Hurvitz","year":"2015","unstructured":"Hurvitz SA, Andre F, Jiang Z et al (2015) Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16:816\u2013829","journal-title":"Lancet Oncol"},{"key":"3499_CR27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813","journal-title":"N Engl J Med"},{"key":"3499_CR28","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814\u20131823","journal-title":"N Engl J Med"},{"key":"3499_CR29","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2016.34.15_suppl.7506","volume":"34","author":"TE Witzig","year":"2016","unstructured":"Witzig TE, Tobinai K, Rigacci L et al (2016) PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 34:7506\u20137506","journal-title":"J Clin Oncol"},{"key":"3499_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1517\/14740338.2014.888056","volume":"13","author":"I Duran","year":"2014","unstructured":"Duran I, Goebell PJ, Papazisis K et al (2014) Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf 13:361\u2013372","journal-title":"Expert Opin Drug Saf"},{"key":"3499_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.04.029","volume":"121","author":"M Deppenweiler","year":"2017","unstructured":"Deppenweiler M, Falkowski S, Saint-Marcoux F et al (2017) Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res 121:138\u2013144","journal-title":"Pharmacol Res"},{"issue":"4","key":"3499_CR32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00280-017-3407-5","volume":"80","author":"L Laborde","year":"2017","unstructured":"Laborde L, Oz F, Ristov M et al (2017) Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer. Cancer Chemother Pharmacol 80(4):869\u2013878","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3499-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:30:49Z","timestamp":1589628649000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3499-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3499"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3499-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2017,12,13]]},"assertion":[{"value":"31 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No financial or other conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}